VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction of conversion from mild cognitive impairment to Alzheimer Disease.

Abstract

Sensitive and accurate biomarkers for the prediction of conversion from mild cognitive impairment (MCI) to Alzheimers Disease (AD) are needed to both support clinical care and enhance clinical trial design. Here, we examined the potential of cerebrospinal fluid (CSF) levels of a peptide derived from a neural protein involved in synaptic transmission, VGF (a non-initialism), to enhance accuracy of prediction of conversion from MCI to AD. The performance of conventional biomarkers (CSF A{beta}1-42 and phosphorylated tau +/- hippocampal volume) was compared to the same biomarkers with CSF VGF peptide levels. It was observed that VGF peptides are lowered in patients with AD compared to controls and that combinations of CSF A{beta}1-42 and phosphorylated tau, hippocampal volume and VGF peptide levels outperformed conventional biomarkers alone (hazard ratio = 2.2 vs. 3.9). VGF peptide levels were correlated most strongly with total tau levels, but not hippocampal volume, suggesting that they serve as a marker for neuronal degradation, but not necessarily in the hippocampus. The latter point suggests that VGF may serve as a more general marker of neurodegeneration. Future work will be needed to determine the specificity of VGF for AD vs. other neurodegenerative diseases.